|

EMDR for Fear of Cancer Recurrence in Patients with Familial Melanoma: a Waiting List Control Trial

RECRUITINGN/ASponsored by Leiden University Medical Center
Actively Recruiting
PhaseN/A
SponsorLeiden University Medical Center
Started2023-11-01
Est. completion2025-07-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06767332

Summary

High fear of cancer recurrence (FCR) impacts patient's quality of life (QoL) and is prevalent among patients with familial melanoma. The main objective is to investigate whether EMDR is effective in treating high FCR in patients with familial melanoma. The study design is a non-blinded, randomized waiting-list controlled trial. Patients aged 18 years or older with familial melanoma can be included. Patients with high FCR will receive a maximum of 4, 90 minutes, EMDR-sessions. The main study parameter is the decrease and level of FCR measured with the Cancer Worry Scale (CWS). The secondary study parameter is quality of life, measured with the EORTC.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* a score of 16 or higher on the FCRI-NL-SF
* 18 years or older
* diagnosed with familial melanoma

Exclusion Criteria:

* insufficient knowledge of the Dutch language.
* acute psychiatric disease (psychosis, suicidal ideation)
* variable dosis of anxiolytics

Conditions6

AnxietyCancerEye Movement Desensitization and ReprocessingFamilial MelanomaFear of Cancer RecurrencePsychological Intervention

Browse More Trials

Cancer trialsAnxiety trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.